Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
10/2005
10/18/2005CA2218054C Solid compositions containing polyethylene oxide and an active ingredient
10/18/2005CA2190016C Improvements in dental floss
10/18/2005CA2156288C Glycerol derivative, device and pharmaceutical composition
10/18/2005CA2113249C Methods and apparatus for creating a gelatin coating
10/18/2005CA2106682C Viscous surface active composition
10/18/2005CA2098834C Wet powder film-forming compositions
10/15/2005CA2738682A1 Soft gel delivery system for treating poultry
10/15/2005CA2504551A1 Process for the preparation of adsorbates of valsartan and/or its solvates or hydrates
10/13/2005WO2005095621A1 Method of regulating gene introduction with use of artificial magnetic material and system therefor
10/13/2005WO2005095566A1 Compositions containing interestified lipids and phytosterol ester, and related methods, with health and nutrition promoting characteristics
10/13/2005WO2005095539A1 Polymersome compositions and associated methods of use
10/13/2005WO2005095390A2 Novel co-precipitate of amorphous rosiglitazone
10/13/2005WO2005095381A1 Dipeptidyl peptidase inhibitors
10/13/2005WO2005094918A1 Solid pharmaceutical preparation for dialysis
10/13/2005WO2005094901A1 Formulations and methods to prepare inhalable buffered methacholine chloride solutions.
10/13/2005WO2005094893A2 Freeze-dried, free-flowing, particulate composition having improved palatability
10/13/2005WO2005094878A1 Composition having antitumor effect
10/13/2005WO2005094843A1 Rapidly disintegrating taste-masked tablet
10/13/2005WO2005094842A1 Vitamin b12-containing compositions and methods of use
10/13/2005WO2005094840A1 Compositions comprising mannose phosphate for vaginal treatment
10/13/2005WO2005094831A1 Sustained-release tablet formulation
10/13/2005WO2005094825A1 Controlled release pharmaceutical composition of tolperisone for oral administration
10/13/2005WO2005094821A1 A medical composition for increasing the medicine safety
10/13/2005WO2005094814A1 External preparation
10/13/2005WO2005094812A1 Nateglinide-containing preparation
10/13/2005WO2005094811A1 Pharmaceutical product containing tranilast
10/13/2005WO2005094809A1 A composition containing a complex comprising a metal ion and a carboxylate ligand having anti-inflammatory activity
10/13/2005WO2005094798A2 Pharmaceutical compositions based on anticholinergics and ccr2 receptor antagonists
10/13/2005WO2005094794A1 Controlled release formulation for oral administration of metformin
10/13/2005WO2005094793A1 Process for preparing a solid pharmaceutical composition
10/13/2005WO2005094792A1 Anionic hydrogel matrices with ph dependent modified release as drug carriers
10/13/2005WO2005094791A1 Preparation of lipid coated cefuroxime axetil
10/13/2005WO2005094790A1 Liposomal formulations
10/13/2005WO2005094789A1 S/o type pharmaceutical preparation and process for producing the same
10/13/2005WO2005094788A1 Fine dispersion of sparingly soluble drug and process for producing the same
10/13/2005WO2005094787A1 Composition and method for dry cow udder protection
10/13/2005WO2005094786A2 Coated tablet formulation and method
10/13/2005WO2005094785A2 Compositions capable of facilitating penetration across a biological barrier
10/13/2005WO2005094784A2 Bifunctional bioadhesive compositions for oral implantology
10/13/2005WO2005094783A2 Serum-stable amphoteric liposomes
10/13/2005WO2005094610A1 Stable coating agent comprising sterol
10/13/2005WO2005094385A2 Non-toxic disinfectant containing a isopropyl alcohol and sesame oil composition with lemon oil and menthol
10/13/2005WO2005094384A2 Methods and compositions for treatment of ion imbalances
10/13/2005WO2005094265A2 Self assembling activation agents targeted using active drug release
10/13/2005WO2005079841A3 Gm1 binding deficient exotoxins for use as immunoadjuvants
10/13/2005WO2005074378A3 Device and method for reducing calorie intake
10/13/2005WO2005062818A3 Treatment of ophthalmic conditions
10/13/2005WO2005061095A9 Process for producing microsphere and apparatus for producing the same
10/13/2005WO2005053658A8 Butylphthalide soft gel capsule and its preparatin procedure
10/13/2005WO2005051290A3 Methods and formulations for the treatment of medical conditions related to elevated dihydrotestosterone
10/13/2005WO2005048990A3 Melt blend dispersions comprising a low water solubility drug and an ethylene oxide-propylene oxide block copolymer
10/13/2005WO2005046634A3 Gastric juice-resistant form of administration
10/13/2005WO2004096118A3 Composition for improving cognition and memory
10/13/2005WO2004074509A3 Reversible attachment of a membrane active polymer to a polynucleotide
10/13/2005WO2004064717A3 Cop 1 for treatment of inflammatory bowel diseases
10/13/2005WO2004062617A3 Composition and method for treatment of bacterial vaginal infections
10/13/2005US20050229264 Recombinant gelatins
10/13/2005US20050228170 B7-like molecules and uses thereof
10/13/2005US20050228049 Administering gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds; treatment of overactive bladder without loss of urine
10/13/2005US20050228048 Stable eye drops containing latanoprost as the active ingredient
10/13/2005US20050228032 Antimicrobial compositions
10/13/2005US20050228001 Methods and compositions for treating platelet-related disorders
10/13/2005US20050227998 Compositions and methods of decreasing nicotine withdrawal
10/13/2005US20050227989 Polycyclic thiazoles as potassium ion channel modulators
10/13/2005US20050227967 Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists
10/13/2005US20050227966 Bazedoxifene acetate formulations
10/13/2005US20050227924 Peyer's patch and/or M-cell targeting ligands
10/13/2005US20050227916 Administering carrier molecule such as albumin conjugated to mannose-6-phosphate; particularly targeting Hepatic Stellate Cells (HSC); glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, Crohn's disease, colitis ulcerosa, glomerulonephritis and sepsis; diagnosis
10/13/2005US20050227913 Reducing the immunogenicity of a therapeutic peptide, polypeptide or protein (Factor VIII) by complexing it with a serine compound, phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid ore a phospholipid containing them; may be used to treat Hemophilia
10/13/2005US20050227911 Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
10/13/2005US20050227910 Local regional chemotherapy and radiotherapy using in situ hydrogel
10/13/2005US20050226974 Natamycin dosage form, process for preparing same, method for preserving a food product and preserved food product
10/13/2005US20050226946 Composition obtained from barley shochu stillage and having effects of inhibiting the onset of alcoholic liver injury and healing it as well as favorable taste, and processing for producing the same
10/13/2005US20050226944 Method for oxygen treatment of unsaturated carbon compounds, novel epoxy-structured material obtained by the method, apparatus for carrrying out the method and a therapeutic composition using the material
10/13/2005US20050226938 reacting mono/di/tri or polycarboxylic acids (e.g.citric acid) with chitosan to form a first solution containing a chitosan nanoparticle that is partially crosslinked to form a core( amide linkage), forming shell on such core having free amino group on the surface with acrylic acid by amidation
10/13/2005US20050226937 Use of hyaluronic acid polymers for mucosal delivery of vaccine and adjuvants
10/13/2005US20050226935 Embolization
10/13/2005US20050226934 Inclusion complexes of active compounds in acrylate (co)polymers and methods for their production
10/13/2005US20050226933 In situ forming hydrogels
10/13/2005US20050226932 Pharmaceutical formulations for itraconazole
10/13/2005US20050226931 Stabilized silver antimicrobial devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide, and an active agent; wound treatment
10/13/2005US20050226930 A bi-layer tablet with the first layer containing dextromethorphan hydrobromide and oxycodone hydrochloride, and the second layer containing carboxy methyl cellulose, sodium chloride, and iron oxide, and does not contain an opoid antagonist; side effect reduction
10/13/2005US20050226929 Controlled release opioid analgesic formulation
10/13/2005US20050226928 Synergistic mixture; hypoglycemic agents; sustained release; bioavailability; metformin with thiazolidinedione compound
10/13/2005US20050226927 Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
10/13/2005US20050226926 Sustained-release tablet composition of pramipexole
10/13/2005US20050226925 Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
10/13/2005US20050226924 Composition comprising itraconazole for oral administration
10/13/2005US20050226923 Venlafaxine compositions in the form of microtablets
10/13/2005US20050226922 Apparatus and method for transdermal delivery of fentanyl-based agents
10/13/2005US20050226921 Non-invasive analysis and controlled dosage transdermal active patch
10/13/2005US20050226920 Method of decreasing nicotine withdrawal symptoms during smoking cessation.
10/13/2005US20050226919 Device for transdermal administration for the treatment of urinary tract disorders
10/13/2005US20050226918 Delivery system for insulin and other therapeutic agents
10/13/2005US20050226915 Method for manufacturing and packaging oral patches with rounded edges
10/13/2005US20050226914 Persistent, durable, broad spectrum antimicrobial activity; for diapers, feminine hygiene products, laundry aids, wound care products, carpets etc
10/13/2005US20050226913 Article for inhibiting microbial growth in physiological fluids
10/13/2005US20050226912 Article and method for applying a coupling agent for a non-invasive optical probe
10/13/2005US20050226911 Article for inhibiting microbial growth in physiological fluids
10/13/2005US20050226910 Transdermal drug delivery system
1 ... 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 ... 2991